Trial reportBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226).
Trial report in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Elevated thymidine kinase 1 expression at baseline predicts poor prognosis in breast cancer patients.Frontiers in oncology · 2026Pooled it
- Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.The oncologist · 2025Trial
- The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.Breast cancer research and treatment · 2024Trial
- Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Prognostic role of thymidine kinase 1 activity in hormone receptor positive metastatic breast cancer. A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2026Review
- Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors.Immuno-oncology technology · 2026Article
- Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.Breast cancer research and treatment · 2026Observational
- Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.JCO precision oncology · 2026Observational
- Acquired resistance in cancer: towards targeted therapeutic strategies.Nature reviews. Cancer · 2025Review
- Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy.Scientific reports · 2025Article
- All Blood Brain Barrier Cell Types Demonstrate Capability to Influence Differential Tenofovir and Emtricitabine Metabolism and Transport in the Brain.ACS pharmacology & translational science · 2024Article
- Drug Metabolism and Transport Capacity of Endothelial Cells, Pericytes, and Astrocytes: Implications for CNS Drug Disposition.bioRxiv : the preprint server for biology · 2024Article
- An Energy-Efficient Test and Predictive Model for Recurrence After Radiotherapy in Localized Intermediate and Advanced Cervical Cancer Were Created Using Thymidine Kinase 1 in Conjunction with Inflammatory Markers and Tumor Markers.International journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 2 countries.
Funding
Abstract
backgroundSome patients with metastatic breast cancer (MBC) stay on endocrine therapy (ET) for years and others progress quickly. Serum thymidine kinase activity (TKa), an indicator of cell-proliferation, is a potential biomarker for monitoring ET and predicting MBC outcome. We have previously reported TKa as being prognostic in MBC in SWOG S0226. Here, new data on progression within 30/60 days post sampling, with a new, FDA approved version of DiviTum
methods1,546 serum samples from 454 patients were assessed, collected at baseline and at 4 subsequent timepoints during treatment. A new predefined cut-off tested the ability to predict disease progression. A new measuring unit, DuA (DiviTum
resultsA DiviTum
conclusionsDiviTum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.